We need to develop new drugs and biologic treatments to effectively treat ischemic stroke and the damage resulting from the stroke in a wider time window so more patients can be eligible for treatment. -- Dr. Cathy Sila, UH Case Medical Center
Cleveland, Ohio (PRWEB) August 07, 2012
A new national study looking at the safety and effectiveness of medication developed from adult stem cells for the treatment of ischemic stroke has opened at University Hospitals (UH) Case Medical Center. The Phase 2 study will use a cell therapy product called MultiStem® developed by the Cleveland-based biotechnology company Athersys. Ischemic stroke is caused by blockage in an artery in or to the brain, that impedes blood flow, and that can result in serious disability or even death.
MultiStem is a proprietary medication made from a patented class of early adult stem cells called Multipotent Adult Progenitor Cells or MAPCs that are obtained from the bone marrow. Hundreds of thousands to millions of doses can be made from the bone marrow cells of one donor. The cells do not come from the patient, so can be made in advance, stored in the hospital and be used off the shelf.
Cathy Sila, M.D., principal investigator of the study, Director of the Stroke and Cerebrovascular Center at UH Case Medical Center, and Professor of Neurology at Case Western Reserve University, said that the objectives of the study are to determine the highest well-tolerated and safest single dose of MultiStem in patients with ischemic stroke and to determine the efficacy of MultiStem on functional outcome in ischemic stroke patients.
“Current therapy for stroke is unfortunately very limited. There is only one drug, tPA, that is approved for use in patients with acute ischemic stroke, and tPA needs to be administered within hours of the onset of the stroke,” said Dr. Sila. “Despite public education and the development of Stroke Centers, only about 4 percent of all ischemic stroke patients presenting to the hospital within 24 hours of their symptoms are eligible for tPA therapy. We need to develop new drugs and biologic treatments to effectively treat ischemic stroke and the damage resulting from the stroke in a wider time window so more patients can be eligible for treatment.”
“Unlike conventional drugs, we believe that MultiStem therapy provides benefit in multiple ways when administered after an acute ischemic stroke,” said Dr. Robert W. Mays, Head of Neuroscience at Athersys. “From our preclinical work, MultiStem cells appear to reduce the local inflammatory response and protect neurons in the brain, while modulating the body’s general immune response and inflammation which leads to additional damage to the brain in the days immediately following the stroke. This is an entirely new concept for how cell therapies may provide benefit following CNS injury, and we are very excited by the potential of MultiStem therapy to treat stroke,” said Dr. Mays.
“We’re trying to improve the functional outcome after a stroke,” said Dr. Sila. If MultiStem therapy ultimately proves to be effective when given at 24-36 hours after the stroke, it could mean that the majority of stroke victims would be eligible for treatment.”
The national study will involve approximately 25 sites with the goal of enrolling 140 patients. It will be double-blind (meaning both the patient and the doctors evaluating the patients won’t know which arm of the study the patient is in), randomized, placebo-controlled. The study is funded by Athersys.
Athersys has advanced four MultiStem programs to clinical stage, including for the treatment of acute myocardial infarction, ischemic stroke, inflammatory bowel disease (partnered with Pfizer Inc.), and to reduce the incidence of severe graft vs. host disease following hematopoietic stem cell transplant.
A video with Dr. Sila and the first UH research participant in the MultiStem trial is available at: http://www.youtube.com/watch?v=bRRTRa7ZEyY&feature=plcp
About University Hospitals
University Hospitals serves the needs of patients through an integrated network of hospitals, outpatient centers and primary care physicians. At the core of our health system is University Hospitals Case Medical Center. The primary affiliate of Case Western Reserve University School of Medicine, University Hospitals Case Medical Center is home to some of the most prestigious clinical and research centers of excellence in the nation and the world, including cancer, pediatrics, women's health, orthopedics and spine, radiology and radiation oncology, neurosurgery and neuroscience, cardiology and cardiovascular surgery, organ transplantation and human genetics. Its main campus includes the internationally celebrated UH Rainbow Babies & Children's Hospital, ranked among the top children’s hospitals in the nation; UH MacDonald Women's Hospital, Ohio's only hospital for women; and UH Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center. For more information, go to http://www.uhhospitals.org
Athersys is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing MultiStem®, a patented, adult-derived "off-the-shelf" stem cell product platform for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation and oncology treatment support, ischemic stroke, and inflammatory bowel disease. The Company has also developed other therapeutic programs, including orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders. Athersys has forged several key strategic alliances and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions in the United States and Europe to further develop its platform and products. More information is available at http://www.athersys.com.